Recent Updates
Recently added Catalysts

Supplemented Formula

Phase 3

Atopic Dermatitis | Unknown | Immunology |Johnson & Johnson|Last Updated: Apr 16, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment380
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02116452Prebiotics in Prevention of AtopyPHASE3 COMPLETED 380Nov 1, 2011 -Apr 16, 20141 Italy
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Cumulative incidence
36 - 48 weeks

Cumulative incidence of atopic dermatitis at 36 and 48 weeks

Secondary Endpoints
Severity
36-48 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Breast MilkNO_INTERVENTIONBreast FED newborns
Standard FormulaPLACEBO_COMPARATORStandard Formula FED newborns
Supplemented FormulaACTIVE_COMPARATORGOS/PDX Formula FED newborns
Interventions
NameTypeDescription
Supplemented FormulaDIETARY_SUPPLEMENT50:50 mixture of GOS/PDX formula will be administered
Unlock Study Design Details
Eligibility Criteria
Age Range1 Week — 24 Weeks
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Gestational age \>37 and \< 42 weeks. 2. Birth weight \> 2500 gr. 3. At risk of atopy (see appendix 1). 4. Informed consent signed by the parents (see appendix 3). Exclusion Criteria: 1. Congenital immunodeficiency 2. Severe congenital disorders or malformations 3. Born to ...

Countries:Italy
Unlock Eligibility Criteria